Breaking newsEAN NewsResearchCOVID-19
Dexamethasone in hospitalized patients with COVID-19 — Preliminary Report
In this controlled, open-label trial recently published in the New England Journal of Medicine, the authors randomly assigned patients who were hospitalised with COVID-19 to receive either oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or usual care.